---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-028787"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:37:00.058088+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology amends bylaws and announces annual meeting voting results

## Summary
- Board approved amended bylaws effective June 17, 2023, enhancing stockholder nomination procedures and complying with universal proxy rules and Delaware law.
- Three Class III directors elected: Scott Garland (35.7M for), Rekha Hemrajani (31.9M for), Jaume Pons (35.6M for), all to serve until 2026.
- Advisory vote on named executive officer compensation passed (35.5M for, 413K against, 9K abstain).
- Ratification of KPMG as independent auditor for FY2023 approved (38.5M for, 8.8K against, 3K abstain).

## SEC filing metadata
- accession: 0000950170-23-028787
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/alxo-20230616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-028787
- JSON: https://secwatch.observer/filing/0000950170-23-028787.json
- Plain text: https://secwatch.observer/filing/0000950170-23-028787.txt

## Key facts
- Governance Changes
  ALX ONCOLOGY HOLDINGS INC: Amended and restated bylaws to enhance stockholder nomination and proposal procedures, revise stockholder meeting provisions, update director/committee/officer provisions, and conform to Delaware law (effective 2023-06-17).
  - Change: bylaw amendment
  - Effective: 2023-06-17
  source text: On June 16, 2023, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Bylaws”) effective as of June 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm
- Shareholder Votes
  ALX ONCOLOGY HOLDINGS INC shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 38,518,146  8,803  3,009 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm
- Shareholder Votes
  ALX ONCOLOGY HOLDINGS INC shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-16 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 35,476,558  413,798  9,213  2,630,389 The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm
- Shareholder Votes
  ALX ONCOLOGY HOLDINGS INC shareholders approved Election of Three Class III Directors at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 1: Election of Three Class III Directors Name of Director For Withheld Broker Non-Votes Scott Garland  35,698,803  200,766  2,630,389 Rekha Hemrajani  31,953,951  3,945,618  2,630,389 Jaume Pons, Ph.D. 35,591,034 308,535 2,630,389 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023028787/0000950170-23-028787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.